Conference Calls
Conference Calls as Podcast
Subscribe to our conference call podcast for free. Learn more about Podcasting on Wikipedia.
Copy podcast address:
Subscribe with iTunesRecent Conference Calls
02/25/2010 - Year-end 2009 and Q4 Results
MorphoSys published its Annual Financial Results 2009 on February 25, 2010. In conjunction with that, the Company held a conference call to further discuss the financial and operational results.
Download MP3 (12,6 MB) Feb 25, 2010 YearEnd-Analyst Conf. 14.00 CET)
Download presentation YE2009 results - press conference and analyst meeting
Download speech YE2009 results - press conference and analyst meeting
Download MP3 (3MB) press conference call(in German only)
Archive
10/28/2009 - Nine Months 2009 Results
MorphoSys published its first nine months’ 2009 results on October 28, 2009. In conjunction with that, the Company held a conference call to further discuss the financial and operational results.
Manuscript of the conference call (PDF, 52 KB)
07/29/2009 - Six Months 2009 Results
MorphoSys published its first six months’ 2009 results on July 29, 2009. In conjunction with that, the Company held a conference call to further discuss the financial and operational results.
Manuscript of the conference call (PDF, 60 KB)
04/28/2009 - Three Months 2009 Results
MorphoSys published its first three months’ 2009 results on April 28, 2009. In conjunction with that, the Company held a conference call to further discuss the financial and operational results.
Manuscript of the conference call (PDF, 50 KB)
02/26/2009 - Year End 2008 and Q4 Results
MorphoSys published its Annual Financial Results 2008 on February 26, 2009. In order to provide detailed information on this announcement the Management Board of MorphoSys AG held a public conference call and live audio webcast.
YE 2008 Press Conference & Analyst Meeting - Presentation (PDF)
YE 2008 Press Conference & Analyst Meeting - Manuscript (PDF, 237 KB)
11/26/2008 - Antibody Alliance with Galapagos
In November 2008, MorphoSys and Galapagos NV announced the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
Replay of slide presentation
Download Presentation (PDF, 1,7 MB)
Manuscript of the conference call (PDF, 145 KB)
01/16/2008 - Update on MOR103 Program
MorphoSys recently announced that it has submitted a clinical trial application (CTA) to initiate a phase 1 trial using the HuCAL-derived antibody MOR103 for the treatment of Rheumatoid Arthritis.
In order to provide detailed information on this announcement the Management Board of MorphoSys AG held a public conference call and live audio webcast on Wednesday, January 16, 2008.
Download manuscript of the conference call
12/03/2007 - New Strategic Alliance with Novartis
MorphoSys announced the formation of one of the most comprehensive strategic alliances in the discovery and development of biopharmaceuticals with Novartis. The deal is aimed at establishing a pipeline of innovative drugs, and combines MorphoSys’s and Novartis’s research, development, manufacturing and commercialization capabilities.
In order to provide detailed information on this announcement the Management Board of MorphoSys AG held a public conference call and live audio webcast on Monday, December 03, 2007.
Manuscript of the conference call (PDF, 94 KB)
Slide presentation (PDF, 2,1 MB)
Press Release